Why Exact Sciences' Report Should 'Allay Fears Of A Market Slowdown'
Exact Sciences(US:EXAS) Investorsยท2025-11-04 15:32TESLA WATCH: Elon Musk Pay Deal In FocusExact Sciences (EXAS) stock surged Tuesday on a broad third-quarter beat that "should allay fears of a market slowdown," an analyst said.The company is well known for Cologuard, a stool-based test that detects colon cancer. Screening revenue, which includes Cologuard tests, grew 22% to $666 million, easily topping forecasts for $637 million. Precision oncology revenue, which includes a breast cancer test, jumped 13% to $184 million. That beat expectations for $173 mil ...